Larimar Therapeutics, Inc. (LRMR): Total Assets
$145.84M
As of 2025-12-31
$165.30M
As of 2026-06-30
+4.9%
3-year compound annual growth
+6.9%
5-year compound annual growth
-2.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $145.84M | -27.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $200.22M | +108.7% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $95.94M | -24.1% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $126.41M | +60.7% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $78.67M | -24.9% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $104.69M | n/m | 2022-03-25, Balance as of period end |
| 2019-12-31 | $5.20M | -95.7% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $121.76M | +15.4% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $105.51M | -19.8% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $131.62M | -30.4% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $189.11M | +60.9% | 2017-03-10, Balance as of period end |
| 2014-12-31 | $117.52M | +208.1% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $38.14M | n/a | 2015-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $145.84M | -27.2% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $150.08M | -24.6% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $150.83M | +114.5% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $140.72M | +133.4% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $151.57M | +25.7% |
| Veradermics, Inc (MANE) | 2025-12-31 | $152.62M | +174.8% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $138.29M | +43.5% |
Compare LRMR, XBIT, PRLD, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗